Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 351 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Failure, Kidney Transplant Clear all
Recruiting No phase listed Observational

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

NCT01644903
View directory record Official record
Conditions
Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 14, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional

Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study

NCT06337942
View directory record Official record
Conditions
Bladder Disease, Bladder, Neurogenic, Bladder Cancer, Kidney Failure
Interventions
Bladder Transplantation, Combined Kidney and Bladder Transplantation
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 14, 2026, 6:40 PM EDT
Completed Not applicable Interventional Results available

Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens

NCT01653847
View directory record Official record
Conditions
End Stage Renal Failure With Renal Transplant
Interventions
Tacrolimus with MMF, Group 2: Tacrolimus with Everolimus.
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 14, 2026, 6:40 PM EDT
Not yet recruiting No phase listed Observational

Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function

NCT07645599
View directory record Official record
Conditions
End Stage Chronic Renal Failure, Renal Transplant, Microvascular Changes, Microvascular Circulation
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Lumason® contrast agent, DEFINITY®
Diagnostic Test · Drug
Lead sponsor
Roderick Tan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 14, 2026, 6:40 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients

NCT01163799
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Alefacept (ASP0485)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 14, 2026, 6:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

NCT06741072
View directory record Official record
Conditions
Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm, Post-Transplant Lymphoproliferative Disorder
Interventions
Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine, QS21
Procedure · Drug · Biological
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 14, 2026, 6:40 PM EDT
Completed Not applicable Interventional

Obesity Surgery and Kidney Transplant for Patients With Obesity and Renal Failure

NCT02128802
View directory record Official record
Conditions
Severe Obesity, Renal Failure
Interventions
Gastric Bypass, Weight Loss Program
Procedure · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 14, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation

NCT00906204
View directory record Official record
Conditions
End-Stage Renal Disease, Kidney Failure
Interventions
Single-dose rabbit Anti-thymocyte Globulin induction, Divided-dose rabbit Anti-thymocyte Globulin induction
Biological
Lead sponsor
Wright State University
Other
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Tucson, Arizona • Omaha, Nebraska • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 14, 2026, 6:40 PM EDT
Completed Phase 2 Interventional

Reduced Calorie Diet Intervention in Kidney Transplant Recipients

NCT00994838
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
reduced calorie diet
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 14, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Results available

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

NCT00275509
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Thymoglobulin, Daclizumab, Plasmapheresis, Mycophenolate mofetil, Tacrolimus, Dexamethasone, Prednisone, Cytogam
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 14, 2026, 6:40 PM EDT
Withdrawn Phase 2 Interventional

Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk

NCT04473924
View directory record Official record
Conditions
Infection, Transplant;Failure,Kidney
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 14, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

NCT00817206
View directory record Official record
Conditions
Renal Failure
Interventions
LCP-Tacro, Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Oct 14, 2026, 6:40 PM EDT
Withdrawn Phase 4 Interventional

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

NCT04614142
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Hepatitis c
Interventions
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
34 Years to 44 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 14, 2026, 6:40 PM EDT
Completed No phase listed Observational

Live Kidney Donor Study -Renal Function Study

NCT01158742
View directory record Official record
Conditions
Kidney Donation, Kidney Failure, Kidney Transplantation
Interventions
Glomerular Filtration Rate with Iothalamate, Glomerular Filtration Rate with Iohexol
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 14, 2026, 6:40 PM EDT
Active, not recruiting Not applicable Interventional

Hepatitis C Virus (HCV) Positive Kidney Grafts in HCV Negative Recipients

NCT04605679
View directory record Official record
Conditions
Kidney Failure
Interventions
Kidney Transplantation
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 14, 2026, 6:40 PM EDT
Not listed Phase 1 Interventional

Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients

NCT03438773
View directory record Official record
Conditions
Kidney Transplant; Complications, Kidney Transplant Failure and Rejection
Interventions
Envarsus, Tacrolimus
Drug
Lead sponsor
California Institute of Renal Research
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 14, 2026, 6:40 PM EDT
Not yet recruiting Not applicable Interventional

Development and Test of a Communication Skills Training for Transplant Providers - Aims 2 & 3

NCT06182475
View directory record Official record
Conditions
Kidney Disease, Chronic, End Stage Renal Disease, Kidney Replacement
Interventions
EPPComm Provider Training
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Livingston, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 14, 2026, 6:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

NCT05525507
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Conditioning and Stem cell infusion
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 14, 2026, 6:40 PM EDT
Completed No phase listed Observational

Study of the Complications Associated With Certain Stem Cell Transplants

NCT01919099
View directory record Official record
Conditions
Post-Transplant Infections, Post-Transplant Renal Insufficiency, Post-Transplant Pulmonary Complications
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 14, 2026, 6:40 PM EDT
Completed Phase 1Phase 2 Interventional

Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use

NCT00479180
View directory record Official record
Conditions
Hemodialysis Access
Interventions
Vascugel, Placebo Comparator
Biological
Lead sponsor
Pervasis Therapeutics, Inc
Industry
Eligibility
18 Years to 89 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Oct 14, 2026, 6:40 PM EDT
Withdrawn Phase 4 Interventional

Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant

NCT03623568
View directory record Official record
Conditions
Kidney Failure, Kidney Diseases, Hepatitis C
Interventions
glecaprevir/pibrentasvir tablets
Drug
Lead sponsor
Raymond T. Chung, MD
Other
Eligibility
30 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 14, 2026, 6:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Website on Living Kidney Donation for Hispanics

NCT01859871
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Website Intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
2
States / cities
Davis, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 14, 2026, 6:40 PM EDT
Completed No phase listed Observational

Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease

NCT00904579
View directory record Official record
Conditions
Immunocompromised Host, Organ Transplantation, Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 100 Years
Enrollment
19,929,901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Hartford, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 14, 2026, 6:40 PM EDT
Completed Phase 4 Interventional

Pharmacokinetics of Immunosuppressants in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy

NCT02221583
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Astagraf XL, Prograf, Mycophenolate mofetil
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
19 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 14, 2026, 6:40 PM EDT